FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: Cellartis AB (CELLARTIS)

Cellartis ABCellartis is a biotech company focused on applications of hES cell technologies and develops, produces and provides hES cell based products and technologies for the industry and the research community. Cellartis has years of expertise in the derivation, culture and in vitro application of hES cells and will perform R&D towards the scale up of hES cell culture and development of a hES cell-based early human developmental toxicity assay. The current workforce is 40 persons, 35% hold a Ph.D. The company is situated in brand new state-of-the-art facilities with cell culture laboratories prepared to fulfil regulatory legislations from the US FDA as well as the EU. The company was founded in 2001 by a group of world leading scientists from Göteborg University and Sahlgrenska University Hospital, together with a management team with long and relevant industrial experience. Cellartis have several collaboration projects with both academic and industrial partners and have been rewarded grants from the EU, the US National Institutes of Health (NIH) and Juvenile Diabetes Research Foundation (JDRF).

Key staff involved in the project

Raimund Strehl (M), Ph.D., Background: Cell biology, Cell culture technologies, Tissue engineering, hESC's. Position: Principal scientist and laboratory director. Experience: Advanced human cell culture and cell based applications in vitro and in vivo. Human embryonic stem cell technologies. Role: PI

Further information: www.cellartis.com

Top ^